Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
64 participants
INTERVENTIONAL
2017-07-01
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery
NCT03017222
Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations
NCT01637545
Ramosetron on Late PONV (Postoperative Nausea and Vomiting)
NCT05326360
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
NCT01476280
Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting
NCT01806948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Forty two subjects are needed with an α value of 0.05, a power of 0.8, and effect size difference of 0.9.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ramosetron iv at induction (I)
0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
Ramosetron
Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
ramosetron iv at recovery (R)
0.6mg of ramosetron is given to the patients intravenously at end of surgery
Ramosetron
Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramosetron
Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
19 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Konkuk University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ka Young Rhee
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ka Young Rhee, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Konkuk University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lee Sung Ho
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH1160112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.